Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Gilead’s stock traded lower on news that claims will proceed that allege the company delayed the development of newer, safer HIV drugs in order to maximize profits.
For experts on Boston Consulting Group’s generative AI panel, effectively using the technology in the biotech industry will be a collaborative process.
Triumvira Immunologics’ president and chief operating officer Rob Williamson noted that cell therapy companies might still have an uphill battle unless they can differentiate.
Clarivate’s latest Drug to Watch list highlights new modalities shaping drug development, including gene editing and artificial intelligence.
The Massachusetts–based startup will use the Series A funds to advance its pipeline of oral GPR17, CSF1R and TYK2 candidates.
On Sunday, ahead of the J.P. Morgan Healthcare Conference, Alphabet’s artificial intelligence startup Isomorphic Labs secured its first pharma partnerships with Eli Lilly and Novartis worth nearly $3 billion.
Patients treated with AR-15512 showed higher rates of at least a 10-mm improvement in unanesthetized Schirmer’s score, a metric of tear production.
The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 2 at JPM2024.
As the second day of the 42nd J.P. Morgan Healthcare Conference dawned in San Francisco, experts from Boston Consulting Group, Merck, CVC and more provided their outlook on the year ahead.
The affiliate of the Multidisciplinary Association for Psychedelic Studies launched the fundraising effort to support its New Drug Application for an investigational, MDMA-assisted therapy for post-traumatic stress disorder.
GSK has entered into an agreement to buy Aiolos Bio in an effort to strengthen its pipeline of respiratory and inflammatory assets.
Following the FDA’s November announcement of an investigation into 20 cases of T cell lymphoma recipients of CAR-T therapies, a cadre of cancer and cell therapy leaders published their assessment in Nature.
PRESS RELEASES
Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channel
The 34-acre site now supports 200,000 square feet of GMP radiopharmaceutical production, with scalable capacity exceeding one million square feet